AI Analysis | Feedback

An early-stage Loxo Oncology, focused on developing precision cancer drugs.

A clinical-stage Blueprint Medicines, developing targeted small molecule therapies for cancer.

AI Analysis | Feedback

• ELVN-001: A selective small molecule kinase inhibitor developed for the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).
• ELVN-002: A potent and selective small molecule inhibitor targeting HER2 and HER3, designed for the treatment of HER2-driven solid tumors.

AI Analysis | Feedback

Enliven Therapeutics (ELVN) is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors for cancer. As a clinical-stage company, Enliven Therapeutics does not currently have any commercial products approved for sale on the market, nor does it generate revenue from product sales.

Therefore, Enliven Therapeutics does not have "major customers" in the traditional sense of entities purchasing its products.

The company does not currently sell primarily to other companies or to individuals. Its primary activities are research and development, funded by capital raised through equity financing and, potentially, future strategic partnerships or licensing agreements with larger pharmaceutical companies.

Should Enliven Therapeutics successfully develop and commercialize its drug candidates in the future, its customers would typically include the following categories:

• Hospitals and Healthcare Systems: These entities would procure and administer pharmaceutical treatments to patients.
• Specialty Pharmacies and Pharmaceutical Distributors: Companies responsible for the distribution, storage, and dispensing of specialized prescription drugs to patients or other healthcare providers.
• Government Healthcare Programs and Private Payers: Organizations (such. as Medicare, Medicaid, and private insurance companies) that purchase or reimburse for pharmaceutical products on behalf of their beneficiaries.

AI Analysis | Feedback

• Lonza Group AG (LONN.SW)
• WuXi AppTec Co., Ltd. (2359.HK)
• CordenPharma

AI Analysis | Feedback

Sam Kintz is a co-founder of Enliven Therapeutics and serves as its Chief Executive Officer and a member of the Board of Directors. Prior to co-founding Enliven, he was an Executive Director of Research at AbbVie and the Head of Research at AbbVie Stemcentrx. He joined Stemcentrx as Senior Director, Strategy and Business Development. Kintz also served as Vice President, Business Development and Applications, at Biodesy, a biotech startup. He has worked at Roche Venture Fund, where he sourced investment opportunities in the life sciences industry, and as a medicinal chemist at Genentech. His involvement with Stemcentrx, which was acquired by AbbVie, indicates experience with companies that have been sold to an acquirer.

Ben Hohl is the Chief Financial Officer and Head of Corporate Development at Enliven Therapeutics. He joined Enliven from the Healthcare Investment Banking Group at Goldman Sachs & Co LLC, where he worked for nearly a decade. While at Goldman Sachs, Hohl advised biopharmaceutical and life sciences management teams and boards, executing a broad range of strategic and financing transactions, including over 50 deals, totaling over $75 billion in M&A, equity, and debt financings. He does not have a pattern of managing companies backed by private equity firms directly as an executive, but his investment banking background involved advising on such transactions.

Joe Lyssikatos is a co-founder of Enliven Therapeutics and serves as its Chief Scientific Officer. Before co-founding Enliven, he was Vice President of Medicinal Chemistry and DMPK at Biogen. His prior experience also includes roles as an Executive Director at AbbVie, Staff Scientist at Genentech, and Senior Director at Array Biopharma, and he began his pharmaceutical career at Pfizer Groton.

Anish Patel is a co-founder and Chief Operating Officer of Enliven Therapeutics. Previously, Patel was the Head of Medical Affairs at AbbVie Stemcentrx. He contributed to building out commercial and medical affairs capabilities at Pharmacyclics for Imbruvica®, a period that culminated in the company's acquisition by AbbVie for $21 billion. He has also held leadership roles at MedImmune/AstraZeneca and Berlex/Bayer.

Helen Collins is the Chief Medical Officer at Enliven Therapeutics. She joined Enliven after serving as Chief Medical Officer at Five Prime Therapeutics, a role she held through its acquisition by Amgen. At Five Prime, she led the development of an investigational targeted antibody, bemarituzumab (anti-FGFR2b), which was granted Breakthrough Therapy Designation by the U.S. FDA.

AI Analysis | Feedback

The key risks to Enliven Therapeutics (ELVN) primarily revolve around the inherent challenges faced by clinical-stage biopharmaceutical companies. These risks are:

1. Clinical Trial Outcomes and Regulatory Hurdles: As a clinical-stage company, Enliven's success is heavily dependent on the successful outcomes of its ongoing and future clinical trials for product candidates like ELVN-001 and ELVN-002. Any setbacks, delays, or failures in these trials, or the inability to obtain regulatory approvals from agencies like the FDA, would significantly impede the company's ability to commercialize its therapies. This is consistently highlighted as an inherent risk in the biotechnology industry.
2. High Research and Development Expenses and Need for Additional Capital: Enliven Therapeutics is currently a pre-revenue company, which is typical for its stage, and reports significant net losses due to substantial research and development (R&D) expenses. While recent funding rounds have bolstered its cash reserves, there remains an ongoing need for considerable additional capital to fund its operations and advance its drug pipeline. This could lead to future equity dilution for existing shareholders.
3. Market Competition: Enliven operates in a highly competitive biopharmaceutical market. Its lead product candidate, ELVN-001, targets chronic myeloid leukemia (CML), which is described as a "crowded therapeutic market" with multiple generations of existing kinase inhibitors. The company faces the challenge of differentiating its product candidates and securing market share against established therapies and other companies developing similar treatments.

AI Analysis | Feedback

AI Analysis | Feedback

Enliven Therapeutics (ELVN) is a clinical-stage biopharmaceutical company with key product candidates targeting specific oncology indications. The addressable markets for their main products are as follows:

• ELVN-001 for Chronic Myeloid Leukemia (CML): The global market for Chronic Myeloid Leukemia treatment is projected to be approximately $8.86 billion in 2025. Other estimates for the global CML treatment market in 2025 range from $8 billion to $9.04 billion.
• ELVN-002 for HER2-mutant Non-Small Cell Lung Cancer (NSCLC): The global market size for HER2-mutant Non-Small Cell Lung Cancer was estimated at approximately $6.2 billion in 2024. The market is expected to grow significantly, with projections reaching $12.3 billion by 2034.
• ELVN-002 for HER2-positive Breast Cancer: The global HER2-positive breast cancer market size is projected to reach approximately $10.96 billion in 2025.

AI Analysis | Feedback

Enliven Therapeutics (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company with expected revenue growth drivers over the next 2-3 years primarily centered on the progression of its lead drug candidate, ELVN-001. While the company is currently unprofitable, analysts forecast significant revenue growth, anticipating the eventual commercialization of its pipeline.

The key drivers of future revenue growth for Enliven Therapeutics include:

1. Advancement of ELVN-001 into Pivotal Phase 3 Trials: Enliven Therapeutics plans to initiate its first Phase 3 pivotal trial for ELVN-001 in 2026 for chronic myeloid leukemia (CML). This critical step is essential for gathering the efficacy and safety data required for regulatory approval and eventual commercialization.
2. Potential Market Entry and Commercial Launch of ELVN-001: Based on positive Phase 1 clinical results that compare favorably to historical benchmarks for approved BCR::ABL1 tyrosine kinase inhibitors (TKIs), the successful completion of later-stage trials and subsequent regulatory approval of ELVN-001 for CML would represent the company's first significant revenue stream.
3. Targeting Specific CML Patient Populations with ELVN-001: ELVN-001 has demonstrated activity against the T315I mutation, a common BCR::ABL mutation that confers resistance to many approved TKIs. This characteristic, combined with its potential for improved tolerability and convenience for patients with comorbidities, positions ELVN-001 to address unmet needs in specific CML patient segments, driving market penetration and adoption.
4. Expansion of ELVN-001 Across CML Treatment Lines: Enliven believes ELVN-001 has the potential to become an improved treatment option across all lines of therapy for CML. Should this broader applicability be realized through clinical evidence and regulatory clearances, it would significantly expand the drug's total addressable market and contribute substantially to revenue growth.

AI Analysis | Feedback

Share Repurchases

No significant share repurchases were reported over the last 3-5 years.

Share Issuance

• Enliven Therapeutics issued $163 million in common equity during the first quarter of 2023.
• An additional $90 million in common equity was issued in the first quarter of 2024.
• The company raised approximately $230 million through a public equity offering in the second quarter of 2025.

Inbound Investments

• In October 2022, Enliven Therapeutics completed a merger with Imara, which included approximately $165 million in concurrent private financing, co-led by Fairmount and Venrock Healthcare Capital Partners.
• The company's total funding, as of September 2025, was $140 million over five rounds, with the latest being a $90 million Post-IPO round on March 21, 2024, from investors including Orbimed, Roche, and 5AM Ventures.

Outbound Investments

Enliven Therapeutics has not made any investments in other companies or acquisitions.

Capital Expenditures

• Capital expenditures have been relatively low, with reported values ranging from $0.01 million to $0.61 million annually over the last five years.
• Research and development (R&D) expenses, a primary focus for the company, increased to $80.8 million for the full year 2024, up from $64.6 million in 2023.
• R&D expenses for the second quarter of 2025 were $21.5 million, reflecting ongoing investment in advancing its clinical pipeline, particularly for ELVN-001 and ELVN-002.